Unresectable Gastroesophageal Junction Adenocarcinoma Active Not Recruiting Phase 1 Trials for Pembrolizumab (DB09037)

IndicationStatusPhase
DBCOND0113409 (Unresectable Gastroesophageal Junction Adenocarcinoma)Active Not Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04522336Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal CancerTreatment